CTXR 241220 1.00P (CTXR241220P1000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

CTXR241220P1000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 15 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Citius Pharmaceuticals Entered Into Definitive Agreements For The Purchase Of An Aggregate Of 12M Shares Of Its Common Stock And Accompanying Warrants To Purchase Up To An Aggregate Of 12M Shares Of Its Common Stock, At A Purchase Price Of $0.25 Per...
BenzingaNov 15 13:32 ET
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
PR NewswireNov 15 13:30 ET
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 12 10:31 ET · Ratings
Citius Pharmaceuticals' Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
TipRanksNov 12 10:25 ET · Ratings
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 12 08:33 ET · Ratings
Citius Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow JonesNov 12 07:44 ET · Ratings

Comments

萬軍無兵策天鳳

Nov 16 00:06

$Citius Pharmaceuticals (CTXR.US)$ 增发时新闻里是这么写的“Citius Pharma's ability to regain compliance with and continue to meet Nasdaq's continued listing standards; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA”

Stock_Drift

Nov 15 12:55

$Citius Pharmaceuticals (CTXR.US)$

Buzz killington

Nov 14 09:50

$Citius Pharmaceuticals (CTXR.US)$ lmao what a scam piece of shit they go and have the scam institutions put out a bunch of high ratings just to crash it on everyone buying in good thing I seen the manipulation in the book and got out with only a 88 dollar loss could have been thousands

Teddy123

Nov 14 05:50

Has until 3 Dec to go to 1

$Citius Pharmaceuticals (CTXR.US)$
0
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing;

As previously disclosed, on September 12, 2023, Citius Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, for the prior 30 cons...

Teddy123

Nov 12 15:02

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer

$Citius Pharmaceuticals (CTXR.US)$
CRANFORD, N.J., Nov. 11, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced promising preliminary results from an ongoing investigator-initia...